Trial
NCT04174677
Safety and Tolerability of Inebilizumab, VIB4920, or the Combination in Highly Sensitized Candidates Awaiting Kidney Transplantation From a Deceased Donor
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Amgen
Collaborators
—
Condition
Highly Sensitized Patients on Waiting List for Kidney Transplantation
Intervention
Inebilizumab
Why stopped
Stopped due to no enrollment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-06-21